New TAVI Devices

Martin B. Leon, MD

Columbia University Medical Center
Cardiovascular Research Foundation
New York City

CARDIOVASCULAR SUMMIT
TCTAP 2014
19th April 22-25, 2014
COEX, Seoul, Korea
www.summit-tctap.com

Disclosure Statement of Financial Interest
TCTAP2014: Seoul, Korea; April 22-25, 2014
Martin B. Leon, MD

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

Affiliation / Financial Relationship	Company
• Grant / Research Support	• Abbott, Boston Scientific, Edwards Lifescience, Medtronic
• Consulting Fees / Honoraria	• Angioscore, Meril Lifescience, Micell,
• Shareholder / Equity	• Apica, Angiometrix, Backbeat, Caliber, Cappella, Claret, Coherex, Elixir, GDS, Medinol, Mitralign, Valve Medical

New TAVI Devices

Background

New TAVI Devices
Current limitations…

- System profiles still too large for “universal” transfemoral access – entry sheath “OD” (esp. for large valves) generally >18 Fr
- Inaccurate and unpredictable positioning at optimal landing zone (ideally, without need for RV pacing)
- Increased permanent pacemaker requirements
- Increased para-valvular regurgitation
- Increased procedure-related strokes
- 4Rs – recapture, reposition, redeploy, and retrieve (if necessary)

New TAVI Devices
Current limitations…

- **Infrequent but important complications (e.g. coronary occlusion and annulus rupture)**
- **Optimal frame geometry, opening force, hemodynamics, and valve durability**

PVT - The Foundation…

Percutaneous Valve Technologies
Aortic Heart Valve

Polyurethane

23mm max diameter

Bovine pericardium / Stainless steel stent

Edwards *Flex Cath* Delivery System Evolution

Retroflex Delivery Catheter

Retroflex 3



TAVR – 2014
Access Alternatives



New TAVI Devices

Edwards THV Evolution

- *Stainless Steel Frame*
- *Equine Pericardial Tissue*

2004

Cribier-Edwards™ THV 23mm

- *Stainless Steel Frame*
- *Bovine Pericardial Tissue*

2007

Edwards SAPIEN™ THV 23 mm and 26 mm

- *Cobalt-Chromium Frame*
- *Bovine Pericardial Tissue*
- *Semi-closed leaflets*
- *Reduced crimped profile*

2010

Edwards SAPIEN XT ™ THV 23 mm, 26 mm, and 29mm

The New Edwards eSheath



The eSheath expands from 14-16F to 18-20F which facilitates smooth delivery system passage, then returns to a reduced profile once the valve has passed through the sheath



SAPIEN 3 Transcatheter Heart Valve

20, 23, 26, and 29 mm sizes

Bovine Thermafix Tissue Leaflets



External Sealing Ring

Balloon-expandable Cobalt Chromium Frame with larger landing zone



Commander (TF) Delivery System

Final valve positioning controlled with fine adjustment wheel





Button-less locking mechanism

CENTERA Transcatheter Heart Valve

23, 26 and 29mm sizes

Bovine Pericardial Tissue Leaflets



Discrete Valve Designed to Anchor in the Annulus

Self expanding Nitinol Frame

Edwards CENTERA Delivery System

Delivery System

Distal End

- Motorized delivery system designed for single operator use
- Repositionable
- Delivered through a 14 Fr eSheath
- Transfemoral and subclavian approach
- Convenient storage (dry leaflet technology) and shelf-life

Edwards HELIO AR Project Implant Technology



1 *Frame*

The Frame is positioned behind the aortic leaflets

2 *Native Leaflets*

3 *Sapien XT Valve*

The native leaflets are captured between the SAPIEN XT and the Frame

Edwards AR Device:
First-in-Human Procedure

TF Delivery of Frame



Orient the Frame behind the native leaflets and in the base of the aortic cusps

TA Delivery of SAPIEN XT valve

Guide SAPIEN XT valve through the native valve

Implant Alignment

Align SAPIEN XT valve and Frame

Balloon Inflation



Deploy SAPIEN XT valve

Confirmatory Angio

Confirm placement

Medtronic CoreValve Evolut R



- *Outflow shortened and redesigned*
- *More consistent radial force*
- *Extended skirt at inflow*
- *Optimized cover index*
- *Optimal Implant Depth: ~3mm*
- *Porcine pericardium*
- *Supra-annular function*
- *Facilitates post-TAVI coronary access*

Medtronic CoreValve Evolut R System



Design Goals

- ***Full annulus range (18 – 29+mm)***
- ***Anatomical fit for annular sealing***
- ***Less traumatic inflow angle to reduce conduction disturbance***
- ***Optimized frame design and new Nitinol materials for Advanced Durability***

**These devices are not approved in the EU, US or Japan for commercialization.*

EnVeo R Delivery System

Recapturable, Retrievable, Repositionable

CoreValve w/ 18FR Cook Sheath		*EnVeo R w/ InLine Sheath*
18FR	*~4 FR Reduction* →	*18FR*
~22 FR (OD) 7.3mm		*Truly 18FR (OD) 6mm*

Medtronic Engager Valve Design

- Control arms
- Self-expanding nitinol frame and polyester skirt
- Supra-annular valve function
- Bovine pericardial tissue
- True anatomic alignment

Engager TA Delivery System

- Tactile control during deployment
- 29 Fr equivalent TA delivery system
- Integrated introducer sheath
- Three step deployment

The outer diameter of the integrated sheath is 10.7 mm

Engager Direct Aortic Delivery System

The delivery system is designed for aortic access using a mini-sternotomy or mini-thoracotomy



3 ***Inflow Skirt Release Knob***

Ergonomic Front Grip

1 ***Control Arm & Outflow Release Knob***

2 ***Safety Stop - Allows for Commissure Post Release***

Optional Accessories :

Stability Sheath

Tuohy Borst

Suture Collar

New TAVI Devices

Direct Flow Valve – Design

Minimized Risk of Aortic Regurgitation

- Double-ring design for a secure and durable seal
- Complete hemodynamic assessment before final implantation
- Unlimited repositioning for optimized valve placement
- The valve is fully retrievable



Direct Flow System – Design

Precise valve positioning and reduced hemodynamic instability

- Positioning wires allow for controlled adjustments of valve position
- Immediate valve competency upon expansion
- Minimum to no contrast necessary
- No rapid pacing required during positioning
- No post-dilatation used

Treatment range:

- 25mm valve treats 21-24mm annulus
- 27mm valve treats 24-26mm annulus



ACURATE TF™ Aortic Bioprosthesis

SELF-EXPANDING NITINOL

Conforms to native anatomy

3 sizes: 21mm to 27mm

STABILIZATION ARCHES

Flexible

Self-aligning

UPPER CROWN

Supra-annular anchoring

Stable positioning

Tactile feedback

LOWER CROWN

Minimal LV protrusion

Low risk of conduction defects

PERICARDIAL LEAFLETS

Porcine pericardium

Lower profile

PERICARDIAL SKIRT

Inner & outer skirt acts as seal to prevent PVL

ACURATE TF™ 3-Step Implantation

Initial Alignment

1. Open upper crown & gentle pressure forward

2. Open stabilization arches

3. Open lower crown for full deployment

Portico Valve Design Features

- Self expanding stent design: fully repositionable and retrievable
- Bovine pericardium leaflets (intra-annular)
- Porcine pericardium sealing cuff
- Both leaflets and cuff are treated with Linx™ AC treatment*
  - Same anticalcification technology used on St. Jude Medical surgical aortic tissue valves
- 23, 25, 27 and 29mm valves



Portico Valve Design Features

- Large stent cells allows access to coronary ostia
- Annular placement minimizes conduction issues
- Improved seal zone to reduce PVL



Portico Trans-aortic or Subclavian Delivery Systems

- Compatible with 18 F introducer sheath
- Similar design to Transfemoral delivery system
  - 65cm working length



*Until fully deployed

Lotus Valve System

Design Goals

Preloaded delivery system

Intuitive handle design



- Deployed via controlled mechanical expansion
- No rapid pacing
- Functions early
- Central radiopaque marker to aid precise placement
- Fully repositionable and retrievable prior to release
- Adaptive seal to minimize paravalvular leak

Lotus Valve System Design Goals

Minimize Paravalvular Leakage (PVL)



Non – Circular Annulus
+
Irregular calcification
=
PVL

Adaptive seal to mitigate PVL



Adaptive
Seal

Safari Guidewire



LUBRIGREEN™ Pre-Coat PTFE

Leading Competitive Spray-Coat PTFE





The Safari™ guidewire is manufactured by Lake Region Medical and distributed by Boston Scientific Corporation

Transapical JenaValve TAVI system

The JenaValve prosthesis

Deployment	Self expanding
Stent Material	Nitinol
Valve Material	Native porcine aortic valve
Skirt Material	Porcine pericardium
Valve Sizes	23, 25, 27 mm
Annulus Range	21-27 mm



Features

- Feeler guided, anatomically correct positioning
- JenaValve clipping mechanism embraces native AV cusps
- Enables valve deployment without rapid pacing
- Low risk of coronary obstruction

Transapical JenaValve TAVI system

Cathlete plus™ Delivery System: CE Mark September 2013

Access route	Transapical
Catheter	• Sheathless insertion • New: hydrophilic coating of tip *and* shaft
New handle	• Intuitive rotational 3 step deployment • Facilitates full focus on operative field and • One safety button ensures stepwise deployment

Transapical JenaValve TAVI System

Easy 3 step controlled implantation

Step 1
Release of positioning feelers

Step 2
Clipping of AV cusps

Step 3
Full deployment

JenaValve – the only TAVI system worldwide with CE mark for **Aortic Regurgitation**

Successful Treatment of Pure Aortic Insufficie
with Transapical Implantation of the JenaVal

Abstract

Introduction

Case Description

Transapical Implantation of a Second-Generation Transcatheter Heart Valve in Patients With Noncalcified Aortic Regurgitation

Moritz Seiffert, MD,* Patrick Diemert, MD,† Dietmar Koschyk, MD,†

replacement after evaluation by an interdisciplinary heart team (logistic EuroSCORE [European System for Cardiac Operative Risk Evaluation] range 3.1% to 38.9%). Procedural and acute clinical outcomes were analyzed.

Results Implantation was successful in all cases without relevant remaining aortic regurgitation or signs of stenosis in any of the patients. No major device- or procedure-related adverse events occurred and all 5 patients were alive with improved exercise tolerance at 3-month follow-up.

Conclusions Noncalcified aortic regurgitation continues to be a challenging pathology for transcatheter aortic valve implantation due to the risk for insufficient anchoring of the valve stent within the aortic annulus. This report provides first evidence that the JenaValve prosthesis may be a reasonable option in these specific patients due to its unique stent design, clipping the native aortic valve leaflets, and offering promising early results. (J Am Coll Cardiol Intv 2013;■:■–■) © 2013 by the American College of Cardiology Foundation

CASE REPORT

aortic valve (JenaValve) implantation for severe aortic
and aortic aneurysm

JENAVALVE
Designed with the patient at heart

September 16, 2013

JENAVALVE TAVI SYSTEM RECEIVES EXTENDED CE MARK APPROVAL FOR TREATMENT OF AORTIC INSUFFICIENCY

Only TAVI System with Indications to treat Aortic Stenosis and Aortic Insufficiency

New TAVI Devices

Colibri TAVR System

1. *Balloon expandable design*
2. *Folded membrane valve design*
3. *Dry leaflet technology; pre-mounted (long shelf life)*
4. *14 F delivery sheath*



Thubrikar TAVR System

- **Single bovine pericardial cut-out used for all three leaflets**
- **The valve has commissure posts**
  - ***Provides proper opening***
  - ***Provides proper coaptation surface***
- **Valve design minimizes sutures**
  - ***No suture holes in moving leaflets (similar to surgical valves)***
- **25mm OD Nitinol frame**
  - ***Designed for up to 23mm annulus***
  - ***Designed for stronger radial force 19-20 mm height***

Venus A-Valve TAVR System (China)

- Self-expanding frame
- Porcine pericardial valve
- Supra-annular
- 23, 26, 29 and 32mm

MyVal TAVR System (India)

- Transcatheter balloon expandable aortic valve system
- Leaflets crafted out using a single piece of bovine pericardial patch
  - “Japanese Origami” technique aiming to minimize tissue stress
- Tissue valve is mounted on a Cobalt Chromium frame
  - Tissue skirt protected with Polyethylene Terephthalate (PET)

Device Components

Frame Module ⟶ *Assembled Device* ⟵ Valve Module

1. Nitinol self-expanding frame module inserted in optimal annular location
2. Valve module is reconstituted in ascending Ao
3. Valve module is docked to frame

"Unique" Valve Medical Design Features

- Ultra-low profile – 12 French delivery system for all valve sizes
- Modular design (frame and valve separate)
- Folded valve design (not crimped)
- 3-D valve leaflet construction
- *In-situ* docking (valve to frame in ascending Ao)
- Coating to reduce Para-valvular regurgitation
- Temporary valve (in descending Ao) for safety

Optimized Leaflet Performance





- Improved valve orifice areas (and lower gradients)
- Superior closing and coaptation profiles



Polymer Coating

Para-valvular leak prevention







- Two-layer pol
- External hydr
- Frame stored
- Following imp
  swells outwar

Endoluminal Sciences





CARDIOVASCULAR RESEARCH FOUNDATION

Single int al invasive



Harvest of ~100m

Isolation of mono s

Implantation via t

**WEBER B, HOERSTRUP SP et al. (2011) European Heart J*

New TAVI Devices

Final Thoughts

New TAVI Devices

- There is striking innovation and diversity in TAVR designs attempting to address the main current clinical and technical limitations.
- The current market leaders (Edwards and Medtronic) have developed impressive next generation pipeline technologies.
- There are 5 new TAVR systems already with sufficient clinical data to have achieved CE approval… and some have interesting differentiating features.
- Additional novel systems are in development focusing on enhanced deliverability, durability and operator convenience (ease-of-use).